Science Raises $400 Million for Sight-Restoring Implant
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Science raised $400 million to fund the European rollout of its PRIMA sight-restoring implant and a planned US launch that still requires FDA approval. The financing is one of the larger medtech raises of the year and gives the company capital to scale manufacturing and commercial operations. The European rollout can proceed now, while the US timeline hinges on the FDA review. What to watch next is the FDA submission and approval path, plus early European adoption and reimbursement decisions.
Muhabbit's AI wrote this summary in its own words from The Defiant's report. It can get details wrong, so check the source.
Named in this story
PRIMA, Science, FDA